0001562180-24-000484.txt : 20240117
0001562180-24-000484.hdr.sgml : 20240117
20240117160154
ACCESSION NUMBER: 0001562180-24-000484
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240116
FILED AS OF DATE: 20240117
DATE AS OF CHANGE: 20240117
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Reine Allan
CENTRAL INDEX KEY: 0001714023
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39634
FILM NUMBER: 24538389
MAIL ADDRESS:
STREET 1: C/O PIERIS PHARMACEUTICALS, INC.
STREET 2: 255 STATE STREET
CITY: BOSTON
STATE: MA
ZIP: 02109
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Foghorn Therapeutics Inc.
CENTRAL INDEX KEY: 0001822462
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 500 TECHNOLOGY SQUARE
STREET 2: SUITE 700
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-586-3100
MAIL ADDRESS:
STREET 1: 500 TECHNOLOGY SQUARE
STREET 2: SUITE 700
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0508
4
2024-01-16
true
0001822462
Foghorn Therapeutics Inc.
FHTX
0001714023
Reine Allan
500 TECHNOLOGY SQUARE
STE #700
CAMBRIDGE
MA
02139
false
true
false
false
Chief Financial Officer
false
Common Stock
53784.00
D
Stock Options (Right to buy)
3.72
2029-09-16
Common Stock
257513.00
257513.00
D
Stock Option (right to buy)
8.77
2030-08-17
Common Stock
91891.00
91891.00
D
Stock Option (right to buy)
16.63
2031-01-27
Common Stock
120000.00
120000.00
D
Stock Option (right to buy)
14.87
2032-01-25
Common Stock
135000.00
135000.00
D
Stock Option (right to buy)
8.38
2033-01-25
Common Stock
90000.00
90000.00
D
The option vested as to 25% of the underlying shares of common stock on September 17, 2020, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.
The option vested as to 25% of the underlying shares of common stock on August 18, 2021, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.
The option vested as to 25% of the underlying shares of common stock on January 28, 2022, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.
The option vested as to 25% of the underlying shares of common stock on January 26, 2023, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.
The option vests as to 25% of the underlying shares of common stock on January 26, 2024, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.
Exit Form 4 filed solely to report the Reporting Person is no longer an officer of the Issuer within the meaning of Rule 16a-1 of the Securities Exchange Act of 1934, as amended.
/s /Adrian Gottschalk, Attorney-in-Fact for Allan Reine
2024-01-17